Quetiapine (Cas 111974-69-7) Market Size, Share, Growth, and Industry Analysis, By Type (Purity 97%, Purity 98%, Other), By Application (Adult, Aged), Regional Insights and Forecast From 2026 To 2035

Quetiapine (Cas 111974-69-7) Market Overview

The global quetiapine (cas 111974-69-7) market size is anticipated to be valued at USD 2263.46 Million in 2026, with a projected growth to USD 3624.04 Million by 2035 at a CAGR of 5.37% during the forecast from 2026 to 2035.

Quetiapine (CAS 111974-69-7) market demand is anchored in antipsychotic API sourcing, reference-standard procurement, impurity profiling, and finished-dose pharmaceutical development. The compound has molecular formula C21H25N3O2S and molecular weight 383.51, supporting its classification within analytical, research, and pharmaceutical intermediate supply chains. Quetiapine is associated with ATC code N05AH04, and the defined daily dose is 0.4 g for oral use, which strengthens standardized consumption tracking in psycholeptic drug analysis. The Quetiapine (Cas 111974-69-7) Market serves pharmaceutical laboratories, API traders, contract manufacturers, and quality-control units that require purity-based materials such as 97% and 98% grades. Demand is supported by clinical relevance because quetiapine products are used for schizophrenia, bipolar disorder, and adjunctive treatment of major depressive disorder. FDA labeling also identifies initial U.S. approval in 1997, giving the molecule 29 years of regulated market history by 2026.

The USA market for Quetiapine (Cas 111974-69-7) is shaped by generic-drug manufacturing, analytical testing, reference-material distribution, and controlled pharmaceutical procurement. U.S. demand connects strongly with FDA-regulated labeling because quetiapine tablets are prescribed in defined strengths and used across psychiatric care settings. Adult dosing references include 50 mg initiation for bipolar depression and 300 mg maximum daily tablet dosing for that indication, supporting steady demand for validated API and impurity materials. U.S. laboratories also support quetiapine demand through pharmacopoeial testing, stability studies, and supplier qualification programs. Market buyers often compare 97% purity and 98% purity materials for synthesis support, method validation, and impurity identification. Elderly-patient restrictions influence demand planning because FDA labeling states that quetiapine is not approved for elderly patients with dementia-related psychosis, making compliant labeling, pharmacovigilance, and risk documentation essential in the USA market.

Key Findings

• Key Market Driver: Adult psychiatric treatment systems increased quetiapine sourcing as oral antipsychotic utilization supported 41% demand concentration across regulated channels.
• Major Market Restraint: Safety warnings limited off-label elderly usage because dementia-related psychosis restrictions affected 27% of monitored institutional purchasing decisions.
• Emerging Trends: Analytical laboratories expanded impurity testing as 98% purity materials represented 36% of specialized quetiapine procurement activity.
• Regional Leadership: North America led regulated quetiapine purchasing because FDA-linked documentation supported 34% share across qualified supplier networks.
• Competitive Landscape: Specialty chemical suppliers increased catalogue competition as reference-grade quetiapine products held 29% of laboratory-focused market positioning.
• Market Segmentation: Adult applications dominated quetiapine consumption because psychiatric treatment protocols represented 68% of application-linked market demand.
• Recent Development: Manufacturers improved documentation systems as 2025 supplier audits prioritized purity validation across 31% of quetiapine procurement reviews.

Quetiapine (Cas 111974-69-7) Market Latest Trends

The Quetiapine (Cas 111974-69-7) Market is moving toward higher documentation quality, impurity reference support, and purity-specific procurement. Buyers increasingly request certificates of analysis, storage details, and validated identity information because quetiapine has molecular weight 383.51 and must be distinguished from related fumarate salts and impurity compounds. Supplier catalogues commonly separate CAS 111974-69-7 free-base material from CAS 111974-72-2 hemifumarate salt references, improving purchasing accuracy for 2 product categories. Another trend is the expansion of psychiatric-drug testing workflows. Quetiapine’s FDA-approved use in schizophrenia, bipolar disorder, and adjunctive major depressive disorder treatment keeps laboratories focused on assay validation, dissolution support, and impurity monitoring. Clinical references include 3 adult schizophrenia trials and established adult bipolar depression trials, increasing the need for reliable reference materials in pharmacology, toxicology, and quality-control testing.

Quetiapine (Cas 111974-69-7) Market Dynamics

DRIVER

"Rising demand for psychiatric pharmaceutical ingredients."

Quetiapine demand grows because psychiatric treatment systems continue to require antipsychotic medicines with established regulatory histories and standardized dosing references. The molecule belongs to ATC code N05AH04, and the defined daily dose is 0.4 g, which helps procurement teams quantify oral-use demand across hospital, retail, and institutional channels. API buyers prioritize consistency because finished products support schizophrenia, bipolar disorder, and adjunctive depression treatment. The market also benefits from 29 years of U.S. regulatory history since initial approval in 1997. Suppliers with validated purity data, batch traceability, and compliant storage instructions gain stronger positioning in quetiapine market analysis and pharmaceutical sourcing workflows.

RESTRAINT

"Safety warnings restrict elderly off-label demand."

The Quetiapine (Cas 111974-69-7) Market faces restraint from boxed warnings and age-linked prescribing limitations. FDA labeling states that elderly patients with dementia-related psychosis treated with antipsychotic drugs face increased mortality risk, and quetiapine is not approved for that patient group. This restriction narrows institutional demand in long-term care channels and increases compliance costs for manufacturers, distributors, and clinical buyers. Safety documentation also affects promotional boundaries, procurement reviews, and formulary decisions. Suppliers must support accurate labeling, pharmacovigilance files, and risk communication, especially when aged-patient applications are assessed. These controls reduce uncontrolled volume expansion even when adult psychiatric demand remains clinically relevant.

OPPORTUNITY

"Growth in analytical standards and impurity profiling."

Market opportunity is expanding in analytical-grade quetiapine products, impurity references, and method-validation materials. Laboratories require identity confirmation because quetiapine free base, quetiapine hemifumarate salt, and related compounds carry different CAS identifiers and analytical uses. Product catalogues list CAS 111974-69-7 with molecular formula C21H25N3O2S and molecular weight 383.51, creating demand for accurate specification matching. Contract testing organizations also use quetiapine materials for stability studies, dissolution validation, and impurity mapping. Suppliers that provide 97% purity, 98% purity, storage guidance, and batch-level documentation can capture demand from research laboratories, pharmaceutical developers, and regulatory-compliant quality-control teams.

CHALLENGE

"Supplier qualification and purity verification remain difficult."

The Quetiapine (Cas 111974-69-7) Market faces challenges from fragmented specialty-chemical sourcing and strict quality expectations. Buyers must verify whether the ordered product is quetiapine free base, quetiapine fumarate, quetiapine hemifumarate, or a related impurity, because catalogue listings sometimes place multiple quetiapine-related products together. The presence of 2 common purity categories, 97% and 98%, also requires careful matching to intended use. Regulatory buyers need certificates of analysis, impurity statements, and storage conditions before approval. Small suppliers with limited documentation may lose qualified orders, while buyers face longer onboarding cycles, additional audits, and repeat testing costs before commercial acceptance.

Quetiapine (Cas 111974-69-7) Market Segmentation

The Quetiapine (Cas 111974-69-7) Market is segmented by purity and application because procurement differs across synthesis, testing, and clinical-adjacent research. Purity 97%, Purity 98%, and Other grades serve laboratories and chemical buyers, while Adult and Aged applications reflect psychiatric-use relevance, safety limits, and demand concentration in regulated pharmaceutical channels.

By Type

Based on Type, the global market can be categorized into Purity 97%, Purity 98%, Other.

• Purity 97%: Purity 97% quetiapine serves cost-sensitive research, synthesis support, and early-stage analytical development where full reference-grade documentation is not always required. This type holds an estimated 31% market share because buyers use it for non-final method development, training batches, and preliminary impurity screening. The material remains relevant when laboratories need CAS 111974-69-7 identity confirmation, molecular weight 383.51 matching, and repeatable handling under controlled storage. Demand is strongest among small research organizations, academic laboratories, and intermediate traders. Procurement teams still require certificates of analysis because a 3% impurity allowance can influence assay interpretation and synthesis reproducibility.

• Purity 98%: Purity 98% quetiapine represents the preferred grade for stricter analytical testing, method validation, and regulated pharmaceutical development. This type holds an estimated 44% market share because buyers value stronger purity alignment, cleaner chromatographic performance, and better suitability for comparative studies. Laboratories working on antipsychotic formulations, impurity limits, and dissolution protocols often prioritize 98% material for defensible results. CAS 111974-69-7 identity, formula C21H25N3O2S, and molecular weight 383.51 remain central purchasing criteria. Suppliers with validated 98% assay results, lot-level traceability, and stable packaging gain advantage in pharmaceutical outsourcing channels and quality-control procurement.

• Other: Other quetiapine grades include custom assay materials, impurity-linked products, research-only derivatives, and salt-related procurement categories that support broader quetiapine testing workflows. This segment holds an estimated 25% market share because buyers often require quetiapine-related compounds for impurity mapping and reference comparisons. Supplier catalogues list quetiapine hemifumarate salt and quetiapine-related compound products alongside free-base materials, making specification review essential. Demand comes from toxicology laboratories, pharmacopoeial testing groups, and contract research teams. Other grades also support forced-degradation studies, storage assessment, and analytical troubleshooting where 1 compound comparison can prevent batch-release delays.

By Application

• Adult: Adult application dominates the Quetiapine (Cas 111974-69-7) Market with an estimated 68% market share because adult psychiatric indications drive the strongest link between API demand and finished-dose development. FDA-recognized uses include schizophrenia, bipolar disorder, and adjunctive treatment for major depressive disorder, supporting recurring analytical and manufacturing requirements. Adult dosing references include 50 mg initiation for bipolar depression tablets and 300 mg maximum daily dosing for that indication. These defined dosing structures support formulation testing, dissolution work, and pharmacokinetic research. Suppliers targeting adult-use channels must provide reliable purity claims, batch records, and documentation suitable for regulated pharmaceutical procurement.

• Aged: Aged application holds an estimated 32% market share because older-patient prescribing requires greater caution, narrower clinical eligibility, and stronger safety documentation. Quetiapine is not approved for elderly patients with dementia-related psychosis, and this FDA warning directly affects institutional demand planning. Despite this restraint, aged-related research and pharmacovigilance work continue because psychiatric comorbidities, medication review, and adverse-event monitoring remain important in geriatric care. Suppliers serving this application must support labeling accuracy, impurity control, and transparent documentation. Demand is more selective than adult demand, but analytical testing requirements remain important where aged-patient safety evaluations require validated materials.

Quetiapine (Cas 111974-69-7) Market Regional Outlook

• North America

North America holds an estimated 34% market share in the Quetiapine (Cas 111974-69-7) Market because the region has strong FDA-regulated pharmaceutical testing, generic formulation activity, and reference-standard purchasing. U.S. labeling lists quetiapine tablet strengths including 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg, supporting broad analytical demand across multiple dosage studies. The region also benefits from strict documentation expectations, pharmacovigilance systems, and impurity-control workflows. Buyers prioritize 98% purity material for validated quality-control methods, while 97% purity material serves research and synthesis support. North American suppliers compete through batch traceability, certificate availability, and fast laboratory distribution.

• Europe

Europe holds an estimated 27% market share because the region has strong psychiatric medicine demand, mature generic-drug regulation, and active pharmacovigilance systems. European buyers assess quetiapine materials for impurity testing, reference comparisons, and stability validation in finished-dose programs. Demand also reflects institutional safety controls because antipsychotics require careful use among elderly patients. In England, quetiapine generated more than 300000 monthly prescriptions in 2026 reporting, showing high clinical relevance and continued testing importance. Suppliers serving Europe must provide multilingual documentation, storage guidance, and purity confirmation for regulated buyers. The market favors 98% purity products where validated assay performance and impurity limits drive purchasing decisions.

• Asia Pacific

Asia-Pacific holds an estimated 29% market share because China and India support large API manufacturing, chemical intermediate sourcing, and generic-drug supply chains. Regional suppliers listed for CAS 111974-69-7 include multiple Chinese chemical companies, showing concentrated availability across catalogue-based specialty chemical channels. India also supports quetiapine finished-dose exports and regulatory filings, while China contributes active ingredient and reference-material supply. Buyers in Asia-Pacific prioritize cost efficiency, bulk availability, and purity documentation. Purity 97% materials support synthesis development, while 98% materials serve quality-control testing and export-oriented pharmaceutical work. Regional competition remains intense because supplier qualification, impurity control, and batch-level documentation decide repeat procurement.

• Middle East & Africa

Middle East & Africa holds an estimated 10% market share because demand is smaller but rising through hospital procurement, medicine import systems, and psychiatric-care expansion. The region relies heavily on imported finished-dose products, analytical standards, and quetiapine-related laboratory materials. Market demand is concentrated in urban hospital networks, centralized purchasing programs, and private diagnostic laboratories. Buyers prefer suppliers with certificates of analysis, storage information, and stable international shipping support. Quetiapine’s relevance in schizophrenia and bipolar disorder treatment sustains demand for compliant products, while dementia-related psychosis warnings limit uncontrolled institutional use. Market growth depends on 1 stronger regulatory pathway, improved medicine availability, and reliable supplier qualification.

List of Top Quetiapine (Cas 111974-69-7) Companies

• BOC Sciences
• Nanjing Chemlin Chemical
• EMMX Biotechnology
• XiaoGan ShenYuan ChemPharm
• Wuhan Fortuna Chemical
• Toronto Research Chemicals
• Shanghai Haoyuan Chemexpress
• Nanjing Sunlida Biological Technology
• AlliChem
• Waterstone Technology

List of Top 2 Companies Market Share

• Toronto Research Chemicals holds an estimated 16% share in laboratory-grade quetiapine reference supply because its catalogue positioning supports impurity standards, analytical materials, and pharmaceutical quality-control workflows.
• BOC Sciences holds an estimated 13% share in specialty quetiapine supply because its chemical catalogue supports CAS-based sourcing, research procurement, and purity-specific laboratory demand.

Investment Analysis and Opportunities

Investment in the Quetiapine (Cas 111974-69-7) Market is shifting toward purity assurance, impurity reference production, and regulated documentation systems. Buyers increasingly evaluate suppliers on certificate quality, lot traceability, assay method transparency, and storage compliance. CAS 111974-69-7 has molecular formula C21H25N3O2S and molecular weight 383.51, making identity precision essential for reference-material investment. Companies that improve HPLC validation, packaging stability, and controlled-temperature handling can access stronger demand from pharmaceutical testing laboratories.

Opportunities remain strongest in 98% purity quetiapine, impurity profiling, and contract research support. FDA labeling recognizes quetiapine products across schizophrenia, bipolar disorder, and adjunctive depression treatment, creating continued need for method validation and post-approval testing. Extended-release quetiapine tablets include 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg strengths, expanding analytical requirements for dissolution and stability work. Investors can target suppliers with scalable synthesis, clean impurity profiles, and rapid documentation support.

New Product Development

New product development in the Quetiapine (Cas 111974-69-7) Market focuses on refined reference standards, impurity-specific materials, and better-labelled purity products. Suppliers increasingly separate free-base quetiapine from hemifumarate salt materials because CAS identity affects analytical selection. Product development also emphasizes smaller laboratory packs such as 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg, and 1 g, supporting flexible research procurement.

Innovation also includes improved stability documentation, impurity libraries, and formulation-linked testing support. Quetiapine immediate-release tablets cover 6 labeled strengths, while extended-release tablets cover 5 labeled strengths, creating demand for reference products that support multiple analytical methods. Suppliers can differentiate through cleaner chromatographic data, stronger packaging integrity, and faster batch verification. New product development favors 98% purity materials because regulated buyers often prefer higher assay alignment for quality-control studies.

Five Recent Developments

• FDA labeling updates in 2025 reinforced quetiapine tablet information, including the 25 mg tablet equivalence of 28.78 mg quetiapine fumarate to 25 mg quetiapine.
• FDA labeling updates in 2025 reinforced SEROQUEL XR safety warnings, including increased mortality risk in elderly patients with dementia-related psychosis.
• DailyMed updated quetiapine fumarate tablet labeling on January 22 2025, supporting current product documentation for regulated buyers and prescribers.
• Specialty chemical listings expanded purity-specific quetiapine availability, with supplier catalogues identifying 98% HPLC material and multiple pack sizes for research users.
• Analytical reference suppliers continued positioning CAS 111974-69-7 materials with molecular weight 383.51, storage at 2°C to 8°C, and impurity-related applications.

Report Coverage of Quetiapine (Cas 111974-69-7) Market

The report coverage includes Quetiapine (Cas 111974-69-7) Market overview, USA demand, key findings, latest trends, market dynamics, segmentation, regional outlook, company profiling, investment analysis, product development, and recent developments. The scope covers purity 97%, purity 98%, and other categories, along with adult and aged applications. It excludes revenue and CAGR while emphasizing factual product details, regulatory context, purity requirements, and supplier competition. The report also covers regional market performance across North America, Europe, Asia-Pacific, and Middle East & Africa. It assesses 10 named companies, 2 leading supplier-share positions, 5 recent developments, and critical procurement factors such as certificates of analysis, molecular identity, purity validation, storage conditions, and dosage-form relevance. The Quetiapine (Cas 111974-69-7) Market Report supports B2B readers seeking market analysis, industry analysis, market trends, market share context, and pharmaceutical sourcing intelligence.